Tracking treatment-resistant changes in childhood acute lymphoblastic leukemia

Tracking Therapy-Resistant Alterations in Childhood Acute Lymphoblastic Leukemia

NIH-funded research St. Jude Children's Research Hospital · NIH-11167570

Looking at genetic changes linked to treatment resistance in children with acute lymphoblastic leukemia to see if they can predict who will relapse.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionSt. Jude Children's Research Hospital NIH-funded
Lab location1 site (Memphis, United States)
Project IDNIH-11167570 on NIH RePORTER

What this research studies

If your child is newly diagnosed with ALL, researchers will analyze leukemia cells from blood or bone marrow taken at diagnosis using advanced genomic tests, including sequencing beyond the usual protein-coding regions. They will search for known and newly discovered genetic alterations that can make leukemia resistant to chemotherapy. The team will combine these genetic findings with clinical information to build new molecular risk models that aim to predict relapse risk earlier. The overall aim is to help guide more personalized treatment choices that could reduce relapse and long-term toxic side effects.

Who could benefit from this research

Good fit: Children (about 0–11 years old) newly diagnosed with acute lymphoblastic leukemia who can provide diagnostic blood or bone marrow samples and clinical follow-up information.

Not a fit: Adults, children with other types of cancer, or patients whose leukemia does not show detectable genetic resistance markers are unlikely to benefit directly from this work.

Why it matters

Potential benefit: Could help identify children at higher risk of relapse early so doctors can tailor treatments to prevent relapse and reduce long-term toxic side effects.

How similar studies have performed: Previous genomic studies have found some resistance mutations in relapsed ALL and improved biological understanding, but more than half of relapses lack known drivers and using these markers prospectively at diagnosis remains largely unproven.

Where this research is happening

Memphis, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Cancer Cause
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.